Ad is loading...
MENU

SAGE Stock Sage Therapeutics (SAGE, $4.91) entered a bearish trend. Expect a Downtrend continuation

A.I.dvisor
at Tickeron.com
Loading...
SAGE - Sage Therapeutics
Bearish Trend Signal
Bearish Trend
Odds of DOWN Trend
Tickeron

Loading...

Price: $4.91
Daily change: $0 (0%)
Daily volume: 1.6M
Capitalization: $300.4M
Industry: Biotechnology
Sage Therapeutics (SAGE, $4.91) is predicted by A.I.dvisor to decline by to $4.71 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended down during the month, the odds of a Downtrend continuation are

SAGE in downward trend: 10-day moving average moved below 50-day moving average on November 04, 2024

The 10-day moving average for SAGE crossed bearishly below the 50-day moving average on November 04, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on SAGE as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SAGE turned negative on October 31, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

SAGE moved below its 50-day moving average on October 30, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SAGE entered a downward trend on October 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAGE advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

SAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.544) is normal, around the industry mean (13.752). P/E Ratio (0.000) is within average values for comparable stocks, (88.017). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.790). SAGE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (2.789) is also within normal values, averaging (224.437).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SAGE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics and medicines for central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
215 First Street
Phone
+1 617 299-8380
Employees
487
Web
https://www.sagerx.com